| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
A dose regimen-finding study to evaluate the safety, tolerability, pharmacokinetics, and activity of oratecan in subjects with advanced malignancies
|
Boland, Patrick M.
|
|
|
90 |
2 |
p. 175-187
|
artikel
|
| 2 |
Correction to: Wide variation in tissue, systemic, and drain fluid exposure after oxaliplatin‑based HIPEC: results of the GUTOX study
|
de Jong, Loek A. W.
|
|
|
90 |
2 |
p. 189-190
|
artikel
|
| 3 |
Ex-vivo activation of a liposomal prodrug of mitomycin C by human tumors
|
Dorot, Shira
|
|
|
90 |
2 |
p. 109-114
|
artikel
|
| 4 |
Mouse pharmacokinetics and metabolism of the phenylurea thiocarbamate NSC 161128
|
Koubek, Emily J.
|
|
|
90 |
2 |
p. 161-174
|
artikel
|
| 5 |
Population pharmacokinetic modelling of imatinib in healthy subjects receiving a single dose of 400 mg
|
Chien, Yi-Han
|
|
|
90 |
2 |
p. 125-136
|
artikel
|
| 6 |
Prospective evaluation of the relationship between response and exposure of total and unbound erlotinib in non-small cell lung cancer patients
|
Kenmotsu, Hirotsugu
|
|
|
90 |
2 |
p. 115-123
|
artikel
|
| 7 |
RELAY, ramucirumab plus erlotinib versus placebo plus erlotinib in untreated EGFR-mutated metastatic non-small cell lung cancer: exposure–response relationship
|
Nakagawa, Kazuhiko
|
|
|
90 |
2 |
p. 137-148
|
artikel
|
| 8 |
Revisiting metronomic vinorelbine with mathematical modelling: a Phase I trial in lung cancer
|
Barlesi, Fabrice
|
|
|
90 |
2 |
p. 149-160
|
artikel
|
Tijdschrift beschrijving